- Home
- AARD
as of 11-02-2026 3:55pm EST
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 97.4M | IPO Year: | 2025 |
| Target Price: | $7.50 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.65 | EPS Growth: | 43.11 |
| 52 Week Low/High: | $0.93 - $16.60 | Next Earning Date: | 11-16-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.84 | Index: | N/A |
| Free Cash Flow: | -54267000.0 | FCF Growth: | N/A |
Earnings Transcripts
SEC 8-K filings with transcript text
2026 Q2 Q2 2026 Earnings
8-K HOLD Aug 11, 2026 · 6% conf.
Q2 2026 Earnings
8-K HOLDAug 11, 2026 · 6% conf.
1D
-2.69%
$7.00
Act: -8.62%
5D
-6.66%
$6.71
20D
+6.21%
$7.64
Transcript text not available. View on SEC.gov →
2026 Q1 Q1 2026 Earnings
8-K May 7, 2026
Q1 2026 Earnings
8-KMay 7, 2026
2025 Q4 Q4 2025 Earnings
8-K Mar 23, 2026
Q4 2025 Earnings
8-KMar 23, 2026
Compare AARD vs Leading Stocks
See how AARD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AARD Aardvark Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.